Find us on:

Interviews with Experts

Dr. Leonard Weinstock
June 10, 2019
Interview with Dr. Leonard Weinstock, President of Specialists in Gastroenterology, and Associate Professor of Clinical Medicine and Surgery at the Washington University School of Medicine
Dr. Leonard Weinstock shares remarkable new cases of LDN successfully used for psoriasis and psoriatic arthritis. He describes the almost total resolution of psoriasis, psoriatic arthritis, and IBS, of one of his patients. Dr. Weinstock also discusses the high response rate among 15 patients with psoriasis who were treated with LDN, and what message we should take from this finding.
Dr. Guttorm Raknes
April 15, 2019
Interview with Dr. Guttorm Raknes of the University Hospital of North Norway and Raknes Research
Guttorm Raknes, M.D., Ph.D. of the University Hospital of North Norway and Raknes Research, studies the impact of low dose naltrexone on the use of other medications among the Norwegian population. In this interview, Dr. Raknes discusses how the use of LDN among patients with rheumatic joint disease (such as rheumatoid arthritis) affected other medications they receive (such as painkillers and immunosuppressants). Dr. Raknes suggests that it's likely that long term use of LDN may help rheumatoid arthritis, and he hopes their study findings will encourage funding of LDN clinical trials.
Dr. Brian Johnson
April 03, 2019
Interview with Dr. Brian Johnson of SUNY Upstate Medical University
As the Director of Addiction Psychiatry at SUNY Upstate Medical University, Dr. Brian Johnson studies pain and pain relief. He considers fibromyalgia to be an autoimmune version of opioid withdrawal, and suggests that both fibromyalgia and opioid withdrawal involve a dysregulation of the opioid system: low opioid tone. He discusses his research using low dose naltrexone to treat both disorders and how LDN therapy is a far superior treatment for treating fibromyalgia.
Dr. Wai Liu
January 19, 2018
Interview with Dr. Wai Liu of St. George's University of London
Dr. Wai Liu, an experienced cancer researcher at St. George’s University of London, researches novel cancer treatments, including modifications to established drug regimens to enhance the effectiveness of chemotherapy. His work includes studying the anticancer effects of low dose naltrexone (LDN), which he discusses in this interview with LDNscience.org.
Dr. Mark Shukhman
January 01, 2017
Interview with Dr. Mark Shukhman of the Northshore University Health System/Private Practice
Dr. Mark Shukhman is a psychiatrist in private practice. He was introduced to LDN around 2011 and has been using it with his patients since then. In this interview, he describes his observations about how patients with sexual dysfunction, addictions of various kinds, and mood disorders are responding to LDN. He discusses his philosophy on when to take LDN, why he thinks LDN works for some patients better than others, and future research that he would like to do.
Dr. Guttorm Raknes
November 13, 2016
Interview with Dr. Guttorm Raknes of the University Hospital of North Norway and Uni Research Health
As an expert in repurposed drugs, Guttorm Raknes, M.D., Ph.D. of the University Hospital of North Norway and Uni Research Health, became extremely interested in low dose naltrexone when patient requests and prescription numbers suddenly skyrocketed. A television documentary reported patients' success with LDN which sparked this "overnight" interest. Dr. Raknes studied the phenomenon and published a report, hoping to encourage support from the Norwegian government to fund clinical trials.
Dr. Burton Berkson
May 01, 2016
Interview with Dr. Burton Berkson of the Integrative Medical Center in Las Cruces, New Mexico, USA.
Dr. Burton Berkson, a highly accomplished integrative physician/researcher who first published about LDN, and combination LDN plus alpha lipoic acid, for pancreatic cancer and B-cell lymphoma, discusses what he has learned about LDN's benefits for a variety of conditions, including notoroiusly difficult-to-treat cancers and autoimmune diseases.
Dr. Phil Boyle
February 01, 2016
Interview with Dr. Phil Boyle, Director of the NaPro Fertility Care Clinic in Dublin, Ireland
Dr. Boyle shares his innovative approach using LDN for gynecological and obstetric disorders that are thought to have underlying deficiencies in endogenous endorphins that respond to LDN. He describes how he began trying LDN with his patients who had both difficulties with fertility and autoimmune disorders, and found LDN to improve both. Over the course of years, his use of LDN has expanded to thousands of patients, and has begun to theorize that, in the case of certain disorders (such as endometriosis and autism spectrum disorders), LDN during pregnancy may have a positive effect on the future health of the resulting children. Observations from clinical practice and directions for future research and clinical applications are described.
Dr. Leonard Weinstock
October 01, 2015
Interview with Dr. Leonard Weinstock, Gastroenterologist, President of Specialists in Gastroenterology, Associate Professor of Clinical Medicine and Surgery, Washington University School of Medicine
Dr. Weinstock shares how he came to learn about LDN and started to treat his patients who had inflammatory diseases such as Crohn’s disease, ulcerative colitis, and post-infectious Irritable Bowel Syndrome. As he continues to research LDN’s effects on a variety of medical conditions, he has learned that LDN is effective in many other conditions such as restless leg syndrome and pain, and most recently sarcoidosis. He shares what he has observed using LDN in his medical practice.
Prof. Angus Dalgleish
August 01, 2015
Interview with Renowned Oncologist Dr. Angus Dalgleish, Professor of Medical Oncology at St George's University of London and Consultant Physician at St. George's Hospital
Professor Dalgleish explains how he learned about LDN from one of his patients and how he researched it by meeting with Dr. Bihari and reviewing patient medical records. He describes the patients he has prescribed LDN and the effects he has observed. Professor Dalgleish discusses how he thinks LDN is potentially very useful in all cancers as a good general adjuvant therapy, and speaks about future directions for LDN research.